Skip to main content
PLOS One logoLink to PLOS One
. 2026 Mar 6;21(3):e0344123. doi: 10.1371/journal.pone.0344123

“It becomes more difficult when people don’t empathize with us”: COVID-19-related stigmatization experienced by survivors in Nepal

Buna Bhandari 1,2,3,*,#, Poshan Thapa 4,#, Amit Timilsina 5, Rajiv Ranjan Karn 6, Haider Ali 7, Ashley Hagaman 8, Archana Shrestha 9
Editor: Habil Otanga10
PMCID: PMC12965614  PMID: 41790720

Abstract

The COVID-19 pandemic caused widespread social disruption, with stigma emerging as a significant challenge for individuals who survived infection. This qualitative study explored the forms, drivers, and impacts of COVID-19-related stigma among survivors in Eastern Nepal. In-depth interviews were conducted with 15 COVID-19 survivors who had reported stigma in a preceding cross-sectional survey. Due to pandemic-related restrictions, interviews were conducted over the phone. Data were analysed thematically following the process outlined by Braun and Clarke. COVID-19 stigma was multifaceted, including social rejection, internalized stigma, and discriminatory practices by community members. Key drivers of stigma included self-directed fear of infection and death, misinformation and limited awareness about COVID-19 transmission and prevention, and a fragile health system and policy responses. Although COVID-19-related stigma may have declined as the pandemic evolved, the findings illustrate how stigma can emerge rapidly during health emergencies that can have social consequences related to trust, disclosure, and help-seeking behavior in future crisis. The study highlights the importance of outbreak preparedness strategies that integrate clear communication, strengthened health system capacity, and social protection measures to mitigate stigma and its harms during future public health crises.

Introduction

The Coronavirus disease (COVID-19) pandemic profoundly impacted individuals’ psychological and mental well-being worldwide. During the pandemic, factors such as anxiety, fear, insecurity, social and emotional isolation, financial hardship, and inadequate health infrastructure compounded the challenges faced by affected populations. Among these challenges, stigma emerged as a critical issue for COVID-19 survivors, exacerbating their physical, emotional, and social vulnerabilities [1,2]. Stigma experienced by survivors was widely reported across countries, with prevalence estimates as high as 79% in China [3], 46% in Ghana [4], and 43.3% in Japan [5]. A pooled analysis of stigma related to infectious diseases, Severe Acute Respiratory Syndrome (SARS), Influenza A virus subtype H1N1, Middle East respiratory syndrome coronavirus (MERS), Zika virus, Ebola virus, and COVID-19, reported an estimated prevalence of 34%, highlighting the widespread nature of stigma during infectious disease outbreaks [6].

Historically, epidemics and pandemics have consistently resulted in severe social consequences, most notably stigma and discrimination [7]. This pattern has been observed in several infectious diseases, including Human Immunodeficiency Virus (HIV), tuberculosis (TB), SARS, Ebola, and H1N1 influenza, with COVID-19 being no exception [8]. Stigma has a detrimental impact on individuals, as demonstrated by its association with HIV. Evidence from HIV research shows that stigma contributes to depression, anxiety, and emotional distress, which in turn leads to diminished quality of life and reduced adherence to treatment protocols [9]. Understanding stigma in the context of COVID-19 among survivors is therefore crucial, given its far-reaching short and long-term consequences.

The World Health Organization (WHO) defines social stigma as the “negative association between a person or group of people who share certain characteristics and a specific disease.” Stigma manifests through labelling, stereotyping, discrimination, differential treatment, and loss of social status [10]. These manifestations can have severe consequences, including job termination, social exclusion, abandonment, and physical violence [10]. Furthermore, stigma drives individuals to conceal their illness, delays healthcare-seeking behaviour, and discourages the adoption of preventive measures [10,11]. These repercussions extend beyond individuals, affecting families, communities, and the healthcare system. In Nepal, research on stigma related to TB, HIV, leprosy, and mental health has found significant impacts on patients’ health, access to care, and quality of life [11].

Understanding the stigma faced by COVID-19 survivors was particularly important during the pandemic period, given documented experiences in Nepal and other settings [12,13]. The nature and magnitude of stigma are highly context-specific, affecting individuals, families, communities, and societal structures at multiple levels [14]. A comprehensive understanding of stigma among COVID-19 survivors can help identify its underlying drivers, develop targeted interventions, and help promote support systems. While several studies in Nepal have examined stigma directed towards healthcare providers and migrant returnees during the pandemic [15], fewer have focused on COVID-19 survivors. Therefore, the primary objective of this study was to explore the forms, impact and drivers of stigma experienced by COVID-19 survivors in the context of Nepal.

Materials and methods

Study design and population

This qualitative study was conducted between May 19 and July 24, 2021, as part of a larger mixed-method research project in Biratnagar Metropolitan City, Koshi Province, Nepal. The first phase of the study began with a cross-sectional survey of 385 COVID-19 survivors who were registered in the government reporting system. This first study aimed to estimate the prevalence of mental health problems experienced by survivors (unpublished). Findings from this quantitative survey indicated that 24.7% (n = 101) of respondents reported experiencing some form of stigma.

For this qualitative study, survivors who reported experiencing any form of stigma in the previous quantitative survey and had provided informed consent for further participation were considered eligible for inclusion in the sampling frame. All 101 survivors had provided their consent to be contacted for participation in future research. Twenty participants were selected purposively by two researchers (BB and PT), ensuring variation in factors such as gender, age, education, occupation and average family size, to facilitate a deeper exploration of their experiences and the underlying factors contributing to stigma faced by them. During follow-up, five declined to participate, citing personal reasons such as lack of time and lack of private space for a phone interview, resulting in 15 participants being interviewed. No specific sample size was predetermined, as recruitment was constrained by feasibility challenges in approaching and enrolling participants during the heightened COVID-19 pandemic. The study reporting was guided by the COREQ checklist to enhance transparency and completeness [16].

Data collection tool and method

To explore the stigma experiences of COVID-19 survivors, an in-depth interview guide was developed, drawing on the socio-ecological framework. The socio-ecological framework, which guided this study, was appropriate because it captures how stigma operates and interacts across individual, interpersonal, and structural levels, enabling a comprehensive examination of the multifaceted experiences of COVID-19 survivors in Nepal [17]. The interview topic guide was initially developed in Nepali in discussion with all co-authors, then translated to English. The overall process was guided by the qualitative methods expert co-author (AH), who has extensive experience working on similar topics across diverse populations globally, including Nepal. The interview guide was designed to examine the nature of stigma, drivers (including underlying structural, social, and individual-level factors), and its impact on COVID-19 survivors. It was pre-tested with two participants, and these interviews were not included in the final analysis.

Given the strict lockdown during the second wave of COVID-19 in Nepal, and to ensure the safety and convenience of both participants and RAs, all interviews were conducted over the phone. We did not use video platforms such as Zoom because many participants lacked access to the internet or computers or the necessary skills to use them. A total of 15 in-depth interviews were conducted with participants who reported experiencing any form of stigma. To assure the quality of the data collected, research Assistants (RAs) with prior qualitative research experience and familiarity with the local context conducted the interviews. This also helped ensure neutrality, thus limiting the risk of researchers’ bias. Before the data collection process, the RAs were thoroughly trained on the study objectives, interview tools, and protocols to ensure quality in data collection. The RAs first contacted the participants who were purposively selected. All chosen participants were accessible via phone, either on their own device or on a family member’s device. During the initial contact, the study objectives, methods, and expectations were explained. As the interviews were conducted virtually, no compensation was provided to participants, and this was clearly communicated during the first contact. If participants consented to take part, they were given two options: to participate in the interview on the same day or to choose an alternative date and time based on their convenience. All interviews were conducted in Nepali. After consent was obtained, the interviews were recorded, and each lasted an average of 35–45 minutes.

Data analysis

The audio-recorded in-depth interviews were transcribed verbatim in Nepali and subsequently translated into English by the RAs for data analysis. Translation validation was ensured by performing a back-translation of two transcripts. To ensure confidentiality, pseudonyms were assigned to participants in the transcripts.

Thematic analysis was employed to analyse the study data, following the six-step process outlined by Braun and Clarke [18]. The analysis process involved multiple stages, including familiarising with the data, generating initial codes using an inductive coding approach, searching for themes, reviewing, defining, naming themes, and producing the final report. To enhance the rigour and reliability of the analysis, three researchers (BB, PT and AT) independently read and coded the transcripts. Inductive coding was conducted to generate data, and codes were described and grouped into sub-themes based on shared characteristics. The sub-themes were then aggregated to form overarching themes, as presented in Table 2. The researchers regularly discussed the codes, themes, and interpretations to compare and refine them. NVivo version 12 software [19] was used to organize and manage the qualitative data.

Ethical consideration

The study was approved by the institutional ethics committee of the Nepal Health Research Council (Reg. No. 2897). As the interviews were conducted remotely, informed verbal consent was obtained from all participants, an approach which was approved by the ethics committee. Before each interview, the RAs re-read the full consent script to participants and allowed time for any questions or clarifications. Once participants confirmed their understanding, verbal consent was audio-recorded. To maintain confidentiality, the consent recordings were stored separately from the interview recordings. RAs also confirmed that the participants were in a comfortable and private space to share their experiences, particularly given that many were confined at home with family members during the lockdown periods. All interview recordings and transcripts were stored securely, and only de-identified data were shared among the authors. To ensure anonymity, the names of individuals, places, and institutions were replaced with pseudonyms in the transcripts and subsequent analysis.

Trustworthiness

We used Lincoln and Guba’s (1989) four criteria: credibility, dependability, confirmability, and transferability to establish trustworthiness in this study [20]. To ensure credibility, we pilot-tested the interview guide and conducted in-depth interviews in Nepali to collect rich information from participants. Research assistants, trained and familiar with the local context, conducted interviews, applying probing and clarification techniques to strengthen data quality. Rich verbatim quotations are presented in the results to illustrate the findings. To enhance dependability, we provide a transparent description of the sampling, recruitment, data collection, and analysis, enabling others to assess the consistency of the process. To increase confirmability, coding was carried out independently by three researchers (BB, PT, and AT), with discrepancies resolved through discussion. The researchers also shared codes with the RAs involved in data collection throughout the coding process. For transferability, we provided thick descriptions of the study participants and the research process, allowing readers to assess the applicability of our findings to other settings with similar contexts.

Results

Characteristics of study participants

Table 1 presents the demographic characteristics of study participants who reported experiencing some form of stigma and discrimination. Nearly half of the participants (46.6%) were aged 31–45, and 53% were male. Most participants (66.6%) had an education level above higher secondary level, and 73.3% were employed at the time of the interview. The majority of the participants (93%) reported having fewer than six family members, as shown in Table 1.

Table 1. Characteristics of study participants included in the in-depth interviews (n = 15).

S. N Age Gender Education Occupation Family size
IDI1 21 Male High School Computer operator 4
IDI2 35 Male Masters Part-time teacher 3
IDI3 50 Male Masters Marketing 4
IDI4 27 Female Bachelors Student 3
IDI5 39 Male Secondary level education Student 3
IDI6 55 Male High School Teacher 5
IDI7 40 Female Primary education Unemployed 4
IDI8 38 Female High School Business 3
IDI9 58 Male Bachelor Accountant 11
IDI10 38 Female High School Business 3
IDI11 46 Female Bachelor Teacher 3
IDI12 26 Male Masters Officer in a Ministry 6
IDI13 38 Female Primary education Ward assistant 3
IDI14 27 Female Master Completed NGO worker 4
IDI15 38 Male Master’s degree in medicine Officer 6

Themes and sub-themes from the data

The qualitative analysis generated 53 codes, which were organized into seven sub-themes and three overarching themes. These themes describe how stigma was experienced and enacted among COVID-19 survivors during the COVID-19 period. Table 2 summarises the themes, sub-themes, and corresponding codes derived from the data.

Table 2. Themes and sub-themes derived from the data.

Theme Sub-themes Codes
Dimensions of multifaceted stigma Stigma experiences among COVID-19 survivors and their families Internalized stigma due to self-directed fear of infection, perceived stigma, strained social relationships, reduced social support, intersecting stigma, discrimination in community and workplace settings, and stigma directed towards family members of COVID-19 survivors.
Stigma practices associated with COVID-19 Forceful quarantine, being treated as untouchable, receiving humiliating taunts, unnecessary attention, hesitance to communicate, stereotyping of COVID-19 infection and infected individuals, media-driven, and bias in healthcare seeking.
Impact of COVID-19-related stigma Well-being of persons with COVID-19 infection Limited access to medicine, lack of support for survivors, anxiety, fear of death, perceived physical weakness, mental stress, exhaustion, lack of confidence, and loneliness.
Fragile interpersonal trust and support Lack of social protection, absence of caregivers during isolation, and inability to support pregnant and postpartum women.
Drivers of COVID-19-related stigma Fear of Covid-19 Fear of contracting the virus, fear of death, inaccessible treatment, social media-amplified fear, high death rates, fear of recurrence, and anticipated discrimination due to/during illness.
Limited information about COVID-19 Lack of knowledge, misconceptions, misinformation on social media, misunderstandings about disease transmission, lack of trust in COVID-19 tests, and limited awareness of protocols and vaccines.
Fragile health system and policy responses Unclear COVID-19 protocols, limited healthcare capacity, lack of equipment, insufficient healthcare personnel, inadequate public health programs, lack of government preparedness, neglect of the social dimension in response, and delayed screening and treatment.
  1. Dimensions of multifaceted stigma

This theme captures the various dimensions of stigma experienced by COVID-19 survivors in Nepal, focusing on their personal encounters with stigma and broader societal practices.

  • 1.1

    Stigma experience among COVID-19 survivors and their families

All participants in this study reported experiencing stigma directed at themselves and, in some cases, their families from community members and neighbours following disclosure of their COVID-19 status. Participants described stigma manifesting in various forms and intensities, such as social avoidance, verbal labelling and altered interactions during their infection. One participant drew parallels between their experience and stigma historically associated with conditions, such as HIV and TB:

There is a shopkeeper nearby, who used to say (neighbour who used to take care of them) “don’t take the money”, or “don’t go near them”.This behaviour made me feel like those persons discriminated due to AIDS or TB, which used to happen in Nepal decades ago. It did make me feel really bad. (IDI 2)

Community-level stigma was widespread once participants’ COVID-19 status was revealed. Participants described community members blocking access to homes, evicting tenants, and labelling homes and streets as Corona Ghar or Corona bato (“Home infected by Coronavirus” or “Street infected by Coronavirus”). While some friends maintained contact remotely due to the lockdown situation, others avoided interaction entirely.

I felt very discriminated... when others found out about my COVID-19 status, they stopped contacting me. When I informed them that I had tested positive, they stopped visiting my home. (IDI 8)

Workplace-related stigma was commonly reported among employed participants. Survivors described being blamed for potential disease transmission and experiencing altered interactions from colleagues, even post-recovery and negative test results. A female participant shared:

Conflicts arose among the staff in our office, and they blamed each other. I had been practising self-isolation and refrained from interacting with others. Since I isolated myself early on, no one could accuse me of spreading the coronavirus to them. But they would swiftly close the door when I was outside. (IDI 3)

Participants reported stigma directed towards their family members by the community. Members of the community even directed negative comments and discriminatory behaviour towards children whose parents contracted COVID-19:

Children also faced it. When they went to buy Cetamol (medicine), people said, ‘their mother is infected, why did you take that money, etc.’ The child thought, ‘Our mom is infected, so this money will not work,’ and they became sad. They behaved discriminately against my sons. (IDI 7)

Direct discrimination from immediate family members was largely absent. However, one participant described internalizing stigma within the family context, where self-directed fear of infection shaped his behaviour toward a critically ill family member. Although family members enacted no discrimination, internalized fear results in self-imposed distancing during illness.

Because the situation was so bad at home, everybody was scared. I was scared, too; being a son, I did not meet my mother even though she was so critical after the COVID-19 infection. (IDI 9)

Several participants also reported a lack of support from government officials, local leaders and community members. Despite seeking assistance, some individuals were denied help and, in some cases, evicted by landlords while facing financial difficulties. One participant stated:

Some individuals who were in home isolation after testing positive for COVID-19 sought assistance from key figures in society, including the police, but received no help. Instead, their landlords compelled them to leave their homes and had to stay at a hotel, even though they were facing financial difficulties. (ID10)

  • 1.2

    Stigma Practice associated with COVID-19

Participants described multiple enacted stigma (experience of discrimination, or negative treatment due to perceived identity, or condition). These include being treated as untouchables, receiving humiliating remarks and being singled out by neighbours. Stigma was perceived as more pronounced in urban areas than in rural regions. One participant shared:

I didn’t get any help at the place where I reside. My friends living far away used to call, talk, and help when needed. But in the village where I live, there was no social support. (IDI 10)

A recurring experience involved shopkeepers refusing to accept cash directly from COVID-19 survivors or discouraging others from receiving their money. One participant recounted the discrimination her children faced.

My sons went to buy medicine when I became severely ill. When they went to buy medicine, they said their mother was Corona positive and refused to take the money. When my sons walked in the road, they made remarks saying their mother was Corona-positive. (IDI 7)

Another reported stigma practice involved publicly disclosing individuals’ COVID-19 status, often resulting in forced quarantine in hotels, even for individuals facing financial hardships. Participants also noted that discrimination often persisted after recovery, with continued reluctance from others to engage with them. Health workers, including doctors and nurses, faced similar experiences and could not quarantine themselves in their homes. A male participant shares:

People even refused to allow infected health workers working in hospitals as doctors or nurses to stay in their homes. There was a widespread fear that they would transmit the virus. (IDI 12)

  1. Impact of COVID-19-related stigma

This theme describes the consequences of stigma on survivors’ physical, psychological, and social well-being.

  • 2.1

    Well-being of the person with COVID-19 infections

Many participants reported that their physical and mental health deteriorated due to the constant discrimination and stigma they faced. Survivors described physical weakness from the infection, compounded by inadequate care, stress, mental exhaustion, and heightened anxiety driven by fears of reinfection and death.

[..] and at that time we had heard a lot of news saying many people had lost their lives abroad because of COVID, and I felt like I would not be able to live now. Corona will take my life too. I had so much stress at that time, which was beyond my thinking. (IDI 13)

Additionally, friends and community members’ lack of empathetic behaviour further undermined participants’ well-being. This resulted in feelings of loneliness, abandonment and a diminished sense of confidence:

Within our family, some of us were infected while others were not infected with COVID-19. The community people suspected (falsely) that the other non- infected members were infected too. The community members used to avoid the non-infected family members while walking through our house and talk behind our backs. They (the non-infected family members) felt that discrimination. No one cared to come and ask how we are dealing with the situation. (IDI 10)

  • 2.2

    Fragile interpersonal trust and support

The lockdown imposed during the COVID-19 pandemic disrupted family connections, leaving many participants isolated from their loved ones. Migrant individuals and those away from their families expressed that the absence of family support hindered their recovery. They believed that being with family could have provided the care and assistance necessary for physical and mental well-being.

Maybe it’s because I didn’t get any support then. I was far from my family during that COVID-19 situation; I think that if my family had been there, they could have helped me get medicine whenever I needed it. (IDI 14)

Discrimination and stigma also led to severe consequences, including the death of individuals due to a lack of community support and resources. One participant recalled a neighbour who passed away because he could not receive even the most basic care:

There was a lot of discrimination. Near my home, due to a lack of care, he was even unable to boil water by himself. At the time of taking him to a hospital, he died. (IDI-12)

  1. Drivers of COVID-19-related stigma

    • Fear of COVID-19

The fear of contracting the virus and dying from it was one of the most commonly cited reasons for stigma. Participants highlighted how the lack of guaranteed treatment or vaccines during the early phase of the pandemic contributed to fear and avoidance of COVID-19 survivors:

Fear!! People had limited knowledge about the disease, its transmission, and its causes. They were afraid of the COVID-19 outbreak, and there was a lack of understanding about disease prevention. (IDI 10)

Participants also described the fear of being forcibly quarantined by authorities, which led many to hide their COVID-positive status, disclosing it only to close family members:

During that time, the main problem was that the people were scared of being taken by the police and used to hide the fact that they had the disease. If any case were found, the area would have been sealed, people would have hesitated to go near the patients, and even the whole family would have faced the same. (IDI 10)

Social media played a significant role in amplifying stigma, often sensationalizing and misrepresenting isolation practices and sharing unscientific information, which negatively impacted survivors:

At the time of being diseased, people are mentally weak and left alone. Social media posts about people in isolation affected patients mentally. It was unpractical and unscientific. (IDI 14)

  • 3.2

    Limited Information regarding COVID-19

Participants attributed stigma to widespread misinformation and limited awareness about COVID-19 transmission, testing, and preventive measures. Many individuals held misconceptions, such as believing that COVID-19 survivors would inevitably die or that the virus remained in the body despite a negative test result:

Corona is transmitted by not wearing a mask properly, staying close, or shaking hands. People should understand these things to stop discriminating against COVID-19 patients. (IDI 6)

Lack of accurate information contributed to discriminatory behaviours, and internalized fear, with some participants describing feelings of shame and hesitancy in social interactions:

Discrimination occurs due to a lack of awareness, nothing more than that. Instead of discrimination, safety measures should be in place, such as maintaining distance. It’s okay not to hug or be too close. Initially, I felt shy and fearful when facing others, fearing negative comments. Even after receiving a negative test report, I still had a lingering fear. (IDI 12).

Several participants emphasized that inadequate dissemination of clear protocols and guidelines contributed to confusion and stigma, and they reflected the importance of community education and awareness during health emergencies.

Had society been well-informed and educated, such discrimination wouldn’t have occurred. I know ummm, for a disease like corona (COVID-19), it is necessary to keep some distance, but there is a standard protocol of 3 meters or 6 meters. All of that happened because of a lack of proper information. (IDI 2)

  • 3.3

    Fragile health system and policy responses

Participants frequently cited weakness in the health system as a major driver of stigma. Limited hospital beds, a shortage of equipment, and untrained healthcare workers (for such a pandemic) compromised COVID-19 care and heightened fear within the community, which fueled stigma:

Even patients were not getting beds in the hospital after spending a long time in the emergency department. I don’t think there was any support from the community health system or government. (IDI 14)

The fear of infection and the lack of guaranteed treatment at a health facility made the discrimination worse. (IDI 2)

Participants also highlighted the government’s lack of preparedness in responding to the pandemic. Issues included inadequate enforcement of COVID-19 protocols, ineffective communication of guidelines, and a lack of concrete plans to address myths and misconceptions. One participant recounted:

We know everything and have a lockdown for prevention, but it still lacks safety measures. Talking about my experience, I returned home from Kathmandu the last time before this second lockdown (second wave). At that time, it was said that vehicles were running under safety measures, maintaining distance, and sanitising, but it was not like that. There were as many passengers as before COVID-19, and without maintaining social distancing. It was so packed, and bus fare was also double or triple the regular amount. And that’s not how to do it; it was not satisfying. (IDI 4)

A widespread lack of trust in the government’s response was evident among participants. One participant shared:

The government did nothing; everything is just empty promises and lectures. It’s just written on paper. Everything is based on books and paper, so we should not expect the government to do this or that or say that the government didn’t do this or that. We ourselves should be aware. (IDI 3)

Recommendations for future preparedness

Participants reflected on their experiences during the COVID-19 pandemic and offered recommendations to strengthen preparedness for future public health emergencies. They emphasized the need for the government to prioritize advanced planning and coordinated response that explicitly addresses stigma alongside biomedical containment strategies. Participants highlighted the importance of clear policies, strategies, and procedures to prevent discrimination and protect the rights of affected individuals during a health crisis.

One participant stressed the need for a formal mechanism to address stigma and discrimination during outbreaks.

Policy about social discrimination should be prepared. It should provide justice for the affected people in a time of need. (IDI 15)

Participants also suggested that the government improve its preparedness by learning from the COVID-19 experience to strengthen social protection measures during future pandemics. Suggestions included timely financial assistance, access to nutrition support, and the provision of uninterrupted access to essential medicines to reduce fear, vulnerability, and stigma among affected populations.

The government should look after coronavirus patients and survivors from low-income backgrounds and provide financial support and supplementation. Some financially unstable coronavirus patients and survivors have to fight against the disease with just a normal diet (meal of dal bhat (rice and lentils)), so a little help there in a proper supplement package and nutrition or through direct financial support would be better. (IDI 5)

Several participants reflected on the role of health insurance during the pandemic, noting that it provided some, albeit partial, financial relief during periods of illness and isolation. Although insurance coverage did not fully offset the broader economic consequences associated with COVID-19, participants viewed it as an important form of financial protection that helped manage healthcare-related expenses. These experiences highlighted the value of strengthening and expanding health insurance coverage and broader social protection mechanisms to prepare for future pandemics.

One thing I had done was insurance. I got the insurance money, and it did cover some expenses at that time. But it is difficult to manage things now. (IDI 10)

Participants highlighted the importance of timely and clear communication during health emergencies. They emphasized that awareness and information campaigns are essential to counter misinformation, reduce fear, and prevent stigma during outbreaks. In this context, participants specifically pointed to vaccination, noting that while vaccines were available during the pandemic, not all individuals were adequately reached or informed.

Awareness campaigns should run so swiftly that everyone should understand this disease. It could also be about vaccination. I have gotten my vaccination, but many haven’t; even for that, awareness is a necessity. (IDI 1)

Discussion

This qualitative study provides valuable insights into the multifaceted experiences of stigmatization among COVID-19 survivors in Nepal. It explores various forms of stigma, impacts, drivers, and potential response considerations. These findings should be interpreted within the specific temporal and social context of the COVID-19 pandemic, particularly periods characterized by uncertainty regarding transmission, lockdown restrictions, and evolving public health guidance. The stigma described by participants reflects experiences during the acute phase of the outbreak and may have diminished as population-level knowledge, vaccination coverage and health system response have improved. Therefore, the relevance of these findings lies in the post-pandemic context in understanding the rapid emergence of stigma during emergencies and identifying response elements that may prevent similar harms during future outbreaks.

The study findings emphasize enacted and associated stigma faced by COVID-19 survivors, particularly interpersonal discrimination from neighbours and community members. Similar patterns of stigma and discrimination toward COVID-19 patients have been documented in other countries [21–23]. For instance, studies from India reported high levels of enacted and internalized stigma among COVID-19 survivors [22]. Research from China also highlighted significant stigma experienced by COVID-19 patients, mainly manifesting as social rejection, financial insecurity, internalized shame, and social isolation, closely aligning with the experiences reported in this study [23]. While some participants interpreted their experiences through comparisons with stigma historically associated with conditions such as HIV or TB, COVID-19-related stigma in this context appears more closely linked to crisis conditions and is likely to follow a more time-limited trajectory [24].

Our study participants reported various forms of enacted stigma, including being treated as untouchables, enduring humiliating remarks, and having their residential areas labelled as “Corona home” or “Corona Street.” Families of COVID-19 survivors also experienced social rejection and discriminatory behaviours from community members. Similar patterns of labelling, discrimination against family members, and social rejection have been documented in studies conducted in Uganda and Jordan [25,26]. Some studies have reported more severe manifestations of stigma, such as physical violence and verbal abuse [22,27,28]. However, participants in our study did not report such extreme experiences.

This study found no reports of direct discriminatory behaviour from immediate family members, whereas most participants experienced stigma from neighbours and community members, consistent with the findings of Regmi et al. [29]. Except for one participant who described internalized stigma driven by self-directed fear of infection, family members were portrayed as supportive rather than discriminatory. Community-level stigma had substantial consequences for participants’ physical and mental well-being, consistent with findings from other settings [30].

The reasons behind stigma and discrimination identified in this study were multifaceted and context specific. Fear of infection, recurrence, and death emerged as primary drivers of stigma, alongside misinformation, inadequate awareness, and limited knowledge about COVID-19 transmission, management, and prevention. The role of misinformation, mainly through digital and social media platforms, has been well-documented during the pandemic [31–33], and appears to have amplified fear-driven response and discriminatory behaviour, especially in low- and middle-income countries (LMICs).

One of the key findings of this study is the link between a fragile health system and policy gaps with the stigmatization of COVID-19 survivors. Participants highlighted several systemic shortcomings, including inadequate preparedness, the lack of comprehensive plans and policies, limited healthcare capacity, insufficient social and behaviour change communication, and the absence of explicit strategies to address the social consequences of the pandemic. These findings align with evidence from other settings, which shows that weak health systems, inadequate governance, and poor communication contributed to stigma during the pandemic [24,27,34,35].

Although COVID-19-related stigma has likely declined in the post-pandemic period, experiences of discrimination, forced isolation, and lack of support may have longer-term implications for trust in institutions and health-seeking behaviour. Such experiences could influence willingness to disclose symptoms or engage with health services during future outbreaks or for other communicable diseases, particularly in contexts characterized by fear and misinformation. These potential implications require further investigation.

Strengths and limitations

A key strength of this study is its exploration of the multi-dimensional nature of COVID-19 stigmatization. This approach allowed for a comprehensive exploration of stigma across individual, interpersonal, and structural levels, as well as its drivers and impacts. The study’s findings provide valuable guidance for policymakers, government officials, and community stakeholders seeking to integrate socio-ecological approaches into strategies to address stigma during public health emergencies such as COVID-19. In addition, the inclusion of participants from diverse backgrounds facilitated a richer understanding of how survivors across various social groups experienced stigma.

The study also has a few limitations. First, data collection was conducted through virtual interviews, which may have limited the ability to observe and capture non-verbal cues in participants’ responses. Second, the self-reported nature of the data introduces potential for recall and social desirability biases, as participants may not fully or accurately recount their experiences of stigma. However, to address this limitation, the study employed a rigorous methodological approach, including pretesting of the interview tool, comprehensive training of research assistants, and probing techniques during interviews to elicit detailed responses. Finally, the findings are specific to the context of Biratnagar Metropolitan City in Nepal and may not be directly transferable to other regions or populations.

Conclusion

This study documents the forms and drivers of stigma experienced by COVID-19 survivors in Nepal during the acute phase of the pandemic. Survivors reported social rejection, internalized stigma, discrimination practices by community members, and negative labelling, shaped by fear of infection, a fragile health system and gaps in policy responses. These experiences adversely affected their physical and mental well-being. Although COVID-19-related stigma has likely diminished in the post-pandemic context, the findings remain important for understanding how stigma can emerge rapidly during health emergencies that can have social consequences related to trust, disclosure, and help-seeking behavior in future crisis. The findings emphasize the need for outbreak preparedness strategies that integrate clear and timely communication, strengthened health system capacity, and social protection mechanisms that reduce vulnerability and fear. By situating COVID-19-related stigma within this temporal context while identifying transferable lessons, this study contributes evidence to inform more socially responsive and equitable responses to future pandemics and emerging infectious disease threats.

Supporting information

S1 File. Additional information.

(DOC)

pone.0344123.s001.doc (55.5KB, doc)

Acknowledgments

We would like to acknowledge the Health Section of the Biratnagar Metropolitan City Office team for providing data, all the Research Assistants who helped with data collection, transcription, and translation, and the Nepal Health Research Council for funding this study.

Data Availability

All relevant data are within the paper and its Supporting information files.

Funding Statement

The study was funded by Nepal Health Research Council provincial grant [Grant number 778]. The funders had no role in study design, data collection and analysis, and preparation of this manuscript.

References

  • 1.Chaudhary U. COVID-19 Sharpens Caste Discrimination in Nepal: Inter Press Service News Agency 2020. [cited 2020 Sep 28]. Available from: https://nepalitimes.com/here-now/covid-19-sharpens-caste-discrimination-in-nepal/ [Google Scholar]
  • 2.Parajuli S. Say no to coronavirus stigmatisation: The Kathmandu Post. 2020. [cited 2020 Sep 28]. Available from: https://kathmandupost.com/columns/2020/08/02/say-no-to-coronavirus-stigmatisation [Google Scholar]
  • 3.Liu R, Nicholas S, Leng A, Qian D, Maitland E, Wang J. The influencing factors of discrimination against recovered Coronavirus disease 2019 (COVID-19) patients in China: a national study. Hum Vaccin Immunother. 2022;18(1):1913966. doi: 10.1080/21645515.2021.1913966 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Osei E, Amu H, Appiah PK, Amponsah SB, Danso E, Oppong S, et al. Stigma and discrimination tendencies towards COVID-19 survivors: evidence from a nationwide population-based survey in Ghana. PLOS Glob Public Health. 2022;2(6):e0000307. doi: 10.1371/journal.pgph.0000307 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Sugiyama A, Miwata K, Kitahara Y, Okimoto M, Abe K, E B, et al. Long COVID occurrence in COVID-19 survivors. Sci Rep. 2022;12(1):6039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Yuan K, Huang X-L, Yan W, Zhang Y-X, Gong Y-M, Su S-Z, et al. A systematic review and meta-analysis on the prevalence of stigma in infectious diseases, including COVID-19: a call to action. Mol Psychiatry. 2022;27(1):19–33. doi: 10.1038/s41380-021-01295-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Craddock S. Sewers and scapegoats: spatial metaphors of smallpox in nineteenth century San Francisco. Soc Sci Med. 1995;41(7):957–68. doi: 10.1016/0277-9536(94)00409-m [DOI] [PubMed] [Google Scholar]
  • 8.Chang S-H, Cataldo JK. A systematic review of global cultural variations in knowledge, attitudes and health responses to tuberculosis stigma. Int J Tuberc Lung Dis. 2014;18(2):168–73, i–iv. doi: 10.5588/ijtld.13.0181 [DOI] [PubMed] [Google Scholar]
  • 9.Rueda S, Mitra S, Chen S, Gogolishvili D, Globerman J, Chambers L, et al. Examining the associations between HIV-related stigma and health outcomes in people living with HIV/AIDS: a series of meta-analyses. BMJ Open. 2016;6(7):e011453. doi: 10.1136/bmjopen-2016-011453 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.A guide to preventing and addressing social stigma associated with COVID-19. COVID-19: Risk communication and community engagement. 2022. Available from: https://www.who.int/publications/m/item/a-guide-to-preventing-and-addressing-social-stigma-associated-with-covid-19 [Google Scholar]
  • 11.Marahatta SB, Amatya R, Adhikari S, Giri D, Lama S, Kaehler N, et al. Perceived stigma of leprosy among community members and health care providers in Lalitpur district of Nepal: A qualitative study. PLoS One. 2018;13(12):e0209676. doi: 10.1371/journal.pone.0209676 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Singh R, Subedi M. COVID-19 and stigma: Social discrimination towards frontline healthcare providers and COVID-19 recovered patients in Nepal. Asian J Psychiatr. 2020;53:102222. doi: 10.1016/j.ajp.2020.102222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Bhattacharya P, Banerjee D, Rao TS. The “Untold” Side of COVID-19: Social Stigma and Its Consequences in India. Indian J Psychol Med. 2020;42(4):382–6. doi: 10.1177/0253717620935578 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Stangl AL, Earnshaw VA, Logie CH, van Brakel W, C Simbayi L, Barré I, et al. The health stigma and discrimination framework: a global, crosscutting framework to inform research, intervention development, and policy on health-related stigmas. BMC Med. 2019;17(1):31. doi: 10.1186/s12916-019-1271-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Singh R, Subedi M. COVID-19 and stigma: Social discrimination towards frontline healthcare providers and COVID-19 recovered patients in Nepal. Asian J Psychiatr. 2020;53:102222. doi: 10.1016/j.ajp.2020.102222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Booth A, Hannes K, Harden A, Noyes J, Harris J, Tong A. COREQ (consolidated criteria for reporting qualitative studies). Guidelines for Reporting Health Research: A User’s Manual. 2014;25:214–26. [Google Scholar]
  • 17.Kilanowski JF. Breadth of the socio-ecological model. J Agromed. 2017;22(4):295–7. doi: 10.1080/1059924X.2017.1358971 [DOI] [PubMed] [Google Scholar]
  • 18.Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101. doi: 10.1191/1478088706qp063oa [DOI] [Google Scholar]
  • 19.QSR International. NVivo Qualitative Data Analysis Software. Available from:https://qsrinternational.com/nvivo/nvivo-products/ [Google Scholar]
  • 20.Guba EG, Lincoln YS. Fourth generation evaluation. Sage Publications; 1989. [Google Scholar]
  • 21.Muhidin S, Vizheh M, Moghadam ZB. Anticipating COVID-19-related stigma in survivors and health-care workers: lessons from previous infectious diseases outbreaks - an integrative literature review. Psychiatry Clin Neurosci. 2020;74(11):617–8. doi: 10.1111/pcn.13140 [DOI] [PubMed] [Google Scholar]
  • 22.Bhanot D, Singh T, Verma SK, Sharad S. Stigma and discrimination during COVID-19 pandemic. Front Public Health. 2021;8:829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Yuan Y, Zhao Y-J, Zhang Q-E, Zhang L, Cheung T, Jackson T, et al. COVID-19-related stigma and its sociodemographic correlates: a comparative study. Global Health. 2021;17(1):54. doi: 10.1186/s12992-021-00705-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Seyed Alinaghi S, Afsahi AM, Shahidi R, Afzalian A, Mirzapour P, Eslami M, et al. Social stigma during COVID-19: a systematic review. SAGE Open Med. 2023;11. doi: 10.1177/20503121231208273 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Amir K. COVID-19 and its related stigma: a qualitative study among survivors in Kampala, Uganda. Stigma Health. 2021. [Google Scholar]
  • 26.Abuhammad S, Alzoubi KH, Khabour O. Fear of COVID-19 and stigmatization towards infected people among Jordanian people. Int J Clin Pract. 2021;75(4):e13899. doi: 10.1111/ijcp.13899 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Dar SA, Khurshid SQ, Wani ZA, Khanam A, Haq I, Shah NN, et al. Stigma in coronavirus disease-19 survivors in Kashmir, India: a cross-sectional exploratory study. PLoS One. 2020;15(11):e0240152. doi: 10.1371/journal.pone.0240152 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Bagcchi S. Stigma during the COVID-19 pandemic. Lancet Infect Dis. 2020;20(7):782. doi: 10.1016/S1473-3099(20)30498-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Regmi PR, Dhakal Adhikari S, Aryal N, Wasti SP, van Teijlingen E. Fear, stigma and othering: the impact of COVID-19 rumours on returnee migrants and muslim populations of Nepal. Int J Environ Res Public Health. 2022;19(15):8986. doi: 10.3390/ijerph19158986 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Cervantes-Guevara G, Maciel-Saldierna M, Elizondo-Hernández E, Cervantes-Pérez LA, Cervantes-Cardona GA, García-Reyna B, et al. Fear of COVID-19 in high school personnel: a survey study in western Mexico. Int J Ment Health Addict. 2022;20(3):1687–94. doi: 10.1007/s11469-020-00473-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Love JS, Blumenberg A, Horowitz Z. The parallel pandemic: medical misinformation and COVID-19. J General Intern Med. 2020;35(8):2435–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Ecker UKH, Lewandowsky S, Cook J, Schmid P, Fazio LK, Brashier N, et al. The psychological drivers of misinformation belief and its resistance to correction. Nat Rev Psychol. 2022;1(1):13–29. doi: 10.1038/s44159-021-00006-y [DOI] [Google Scholar]
  • 33.Khullar D. Social media and medical misinformation: confronting new variants of an old problem. JAMA. 2022;328(14):1393–4. doi: 10.1001/jama.2022.17191 [DOI] [PubMed] [Google Scholar]
  • 34.Sadati AK, Parvizi MM, Forouhari S, Hosseini SA, Jahromi MH, Jafferany M. A qualitative study on stigmatization associated with COVID-19. The Primary Care Companion CNS Disorders. 2022;24(2):40320. [DOI] [PubMed] [Google Scholar]
  • 35.Bhatt N, Bhatt B, Gurung S, Dahal S, Jaishi AR, Neupane B, et al. Perceptions and experiences of the public regarding the COVID-19 pandemic in Nepal: a qualitative study using phenomenological analysis. BMJ Open. 2020;10(12):e043312. doi: 10.1136/bmjopen-2020-043312 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Surangi Jayakody

12 Aug 2025

Dear Dr.  Bhandari,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 26 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Surangi Jayakody, MBBS, MSc, MD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In the ethics statement in the Methods, you have specified that verbal consent was obtained. Please provide additional details regarding how this consent was documented and witnessed, and state whether this was approved by the IRB

3. We note that your Data Availability Statement is currently as follows:

“All relevant data are within the manuscript and its Supporting Information files.”

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

4. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Additional Editor Comments:

Please address the comments of Reviewer 1 as stated in the attached manuscript and the comments of Reviewer 2 given below.

[Note: HTML markup is below. Please do not edit.]

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: N/A

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: I have added comments to the paper. Please check the Word document. Good luck! The major comment from me is to clearly state and explain what stigma framework you used, discuss the broader implications of the findings, as some stigma experiences might not be relevant now and even non-existent.

Reviewer #2: In this research article, authors explored the multidimensional stigma related to COVID 19 and its ecological impact on survivors in Eastern Nepal.

As a qualitative study, authors used a appropriate methodological approach and written it in scientific manner.

However,

The title seems to be longer. If it is concise it would be more attractive.

There are some methodological aspects to be revisited.

1.This is a subsequent study component conducted following a survey according to the authors. When choosing 15 out of 101 eligible participants (even though with purposive sampling method), it is clear if inclusion and exclusion criteria are mentioned if there are.

2. It is great if there is a justification for the sample size of 15. Whether this is according to the saturation or predetermined sample size …??

3. Study instruments –

According to the given facts, authors used a semi structured interviewer guide. The rigour of the facts of the study will depend on the validity of the study instrument used for data collection. Hence, to be more transparent, better to mention

Who developed it?

What scientific methods occupy in the preparation of it?

Did validity check? If so, how?

4. Data collection-

Authors mentioned that the data collected via telephone calls. It is recommended to describe how actually the interviews took place. The way of taking consent, time of the interview (approximate), what happened in the interview, Was it recorded...?

Additionally, did all the chosen participants have access to mobile phones?

If so, did all the selected participants respond?

Were there any payments to the participants for participation in this interview.

5. Ethical considerations-

Other than the informed consent, what other ethical aspects were concerned with?

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PONE-D-24-58430_ED.docx

pone.0344123.s002.docx (185.4KB, docx)
PLoS One. 2026 Mar 6;21(3):e0344123. doi: 10.1371/journal.pone.0344123.r002

Author response to Decision Letter 1


18 Sep 2025

We are grateful to the editors and reviewers for their constructive feedback, which has significantly strengthened our manuscript. In response, we have clarified our methods, and thoroughly revised the manuscript, where requested. A detailed, point-by-point response to each comment is included below and attached in a separate file as well.

Comment from editor:

In the ethics statement in the Methods, you have specified that verbal consent was obtained. Please provide additional details regarding how this consent was documented and witnessed, and state whether this was approved by the IRB

Response: Thank you for your advice. We have added the following information to the ethical consideration section. (See page 6, line 137-148)

The study was approved by the Institutional Ethics Committee of the Nepal Health Research Council (Reg. No. 2897). As the interviews were conducted remotely, informed verbal consent was obtained from all participants, an approach which was approved by the ethics committee. Before each interview, the RAs re-read the full consent script to participants and allowed time for any questions or clarifications. Once participants confirmed their understanding, verbal consent was audio-recorded. To maintain confidentiality, the consent recordings were stored separately from the interview recordings. RAs also checked if participants were in a comfortable space to share their perspectives and experiences, particularly given that many were confined at home with family members during the lockdown. All interview recordings and transcripts were stored securely, and only de-identified data were shared among the authors. To ensure anonymity, real names of people, places, and institutions were replaced with pseudonyms in the transcripts and subsequent analysis.

Data Availability

The provided data available statement stands true.

Comment from reviewer:

Reviewer #1: I have added comments to the paper. Please check the Word document. Good luck! The major comment from me is to clearly state and explain what stigma framework you used, discuss the broader implications of the findings, as some stigma experiences might not be relevant now and even non-existent.

Response: Thank you for your constructive feedback. We have clarified and explained about the stigma framework and boarder implications of the findings in the revised manuscript as presented detailed below

1. Appropriate references

Response: This comment has been addressed.

2. As stigma is understood, described and theorized in different ways it is important that you mention what theory/framework was used for your analysis. For an example you mention 'enacted stigma' in the results section, but it is not defined anywhere. You mention drivers but have not defined what 'drivers' mean?

Response: Thank you for highlighting this. We have added more details on the theory/framework and clarified key terminology in the revised manuscript (lines 92–101 and 235–236)

To explore the stigma experiences of COVID-19 survivors, a semi-structured in-depth interview guide was developed, drawing on the socio-ecological framework. The socio-ecological framework, which guided this study, was appropriate as it captures how stigma operates and interacts across individual, interpersonal, and structural levels, reflecting the analysis of the multi-faceted experiences of COVID-19 survivors in Nepal [17].

The tool was designed to examine nature, drivers (underlying structural, social, and individual-level factors), and the impact of stigma on COVID-19 survivors informed by the Socioecological framework to guide the domains/questions and analysis.

3. Data quality is important in qualitative research. Please do explain how you maintained data quality and trustworthiness and the validity and reliability of findings?

Response: We have explained about the data quality and trustworthiness and the validity and reliability of findings as follows in the revise manuscript. (Page 7, line 150-163)

We used Lincoln and Guba’s (1989) four criteria: credibility, dependability, confirmability, and transferability to establish trustworthiness in this study. To ensure credibility, we pilot-tested the semi-structured interview guide and conducted in-depth interviews in Nepali to collect rich information from participants. Research assistants, trained and familiar with the local context, conducted interviews, applying probing and clarification techniques to strengthen data quality. Rich verbatim quotations are presented in the results to illustrate the findings. To enhance dependability, we provide a transparent description of the sampling, recruitment, data collection, and analysis, enabling others to assess the consistency of the process. To increase confirmability, coding was carried out independently by three researchers (BB, PT, and AT), with discrepancies resolved through discussion. The researchers also shared codes with the research assistants (RAs) involved in data collection throughout the coding process. For transferability, we provided thick descriptions of the study participants (Table 1) and the research process, allowing readers to assess the applicability of our findings to other settings with similar contexts.

4. Authors mention that the sampling frame was people who have had experienced stigma and provided consent. More details are needed how you selected the 15 from the above sampling frame. What criteria was used for purposive sampling?

Response: Thank you. We have provided more details as follows in the revised manuscript. (Page 4, line 81-93)

For this qualitative study, survivors who reported experiencing stigma in the quantitative survey and had provided informed consent for further participation were considered eligible for inclusion in the sampling frame. All 101 survivors had provided their consent to be contacted for participation in future research. The participants were selected purposively by two researchers (BB and PT), maximizing variation in factors such as gender, age, education, occupation, and average family size, to facilitate a deeper exploration of their lived experiences and the underlying factors contributing to stigma among COVID-19 survivors in Nepal. During follow-up, five declined to participate, citing personal reasons such as lack of time and lack of private space to take part in a phone interview, resulting in 15 participants being interviewed. No specific sample size was predetermined, as recruitment was constrained by feasibility challenges in approaching and enrolling participants during the heightened period of the COVID-19 pandemic.

5. You might want to tweak this sentence to introduce the socio-ecological framework and summaries it in one-two sentences.

Response: Thank you for your feedback this has been well addressed in the line 92-96 as follows.

To explore the stigma experiences of COVID-19 survivors, a semi-structured in-depth interview guide was developed, drawing on the socio-ecological framework. The socio-ecological framework, which guided this study, was appropriate as it captures how stigma operates and interacts across individual, interpersonal, and structural levels, reflecting the analysis of the multi-faceted experiences of COVID-19 survivors in Nepal [16].

6. It would be best to add a additional file with characteristic of each 15 participants separately rather than as a summary table. For your quotes to be meaningful there should be a reference for a reader to go back and understand their background (age, gender etc).

Response: This comment has been addressed and table with details characteristics of each participants has been provided in the revised manuscript ( see table 1).

7. I wonder whether you should change the wording of this sub theme. Since some of it does not 'exists' anymore such as forced quarantine? Simply stigma practices associated with covid-19 could work better

Response: Thank you for this feedback. We have made the necessary changes accordingly in the revised result section.

8. As the data is old and while findings on structural stigma can be important to highlight system issues, findings on enacted stigma etc might be old and not relevant anymore. authors must critique more on how to use such data in the future and what is the real implication of having this data out now? Especially considering broader health related stigma.

Response: Thank you for this important feedback. We underscore the implications of our data and findings through an illustration of structural stigma and its impact on health system has been explained in lines 366-383 later in the paragraph.

9. In the results section you declare that 'All participants in this study reported experiencing stigma from their family and community members, manifesting in various forms and intensities during their infection" isn't this contradictory?

Response: While all participants in this study reported experiencing stigma, the source of stigma can be different. While few participants experienced stigma from their family, majority of the participants experience stigma from neighbors and friends. This has been explained in the line 269-276

10. Explain why you didn't use virtual techniques such as zoom or other video conferencing platforms as they could have given you a chance to observe non-verbal cues.

Response: We have clarified our approach in detail in the revised manuscript as follows ( see page 5, line 103-106)

Considering the strict lockdown during the second wave of COVID-19 in Nepal, and to ensure the safety and convenience of both participants and RAs, all interviews were conducted over the phone. We did not use video platforms such as Zoom, as many participants did not have access to the internet, computers or the necessary skills to use such platforms.

Reviewer #2:

In this research article, authors explored the multidimensional stigma related to COVID 19 and its ecological impact on survivors in Eastern Nepal. As a qualitative study, authors used a appropriate methodological approach and written it in scientific manner. However, The title seems to be longer. If it is concise, it would be more attractive. There are some methodological aspects to be revisited.

Response: Thank you for the constructive feedback. We have concise the title and addressed each comment as follows.

1) This is a subsequent study component conducted following a survey according to the authors. When choosing 15 out of 101 eligible participants (even though with purposive sampling method), it is clear if inclusion and exclusion criteria are mentioned if there are. It is great if there is a justification for the sample size of 15. Whether this is according to the saturation or predetermined sample size …??

Response: Thank you for your feedback. The criteria for selection, the purpose of purposive sampling has been explained in the line 78-89.

For this qualitative study, survivors who reported experiencing stigma in the quantitative survey and had provided informed consent for further participation were considered eligible for inclusion in the sampling frame. All 101 survivors had provided their consent to be contacted for participation in future research. The participants were selected purposively by two researchers (BB and PT), maximizing variation in factors such as gender, age, education, occupation, and average family size, to facilitate a deeper exploration of their lived experiences and the underlying factors contributing to stigma among COVID-19 survivors in Nepal. During follow-up, five declined to participate, citing personal reasons such as lack of time and lack of private space to take part in a phone interview, resulting in 15 participants being interviewed. No specific sample size was predetermined, as recruitment was constrained by feasibility challenges in approaching and enrolling participants during the heightened period of the COVID-19 pandemic.

2) Study instruments –

According to the given facts, authors used a semi structured interviewer guide. The rigor of the facts of the study will depend on the validity of the study instrument used for data collection. Hence, to be more transparent, better to mention Who developed it? What scientific methods occupy in the preparation of it? Did validity check? If so, how?

Response: We have clarified all of the approach of development and pretesting of the tool in the revised manuscript as follows (Line 92-103)

The interview topic guide was developed originally in Nepali in discussion with all co-authors then translated to English and was guided by the qualitative methods expert co-author (AH), who has extensive experience working on similar topics across diverse populations globally, including Nepal. The tool was designed to examine nature, drivers, and the impact of stigma on COVID-19 survivors informed by the Socioecological framework to guide the domains/questions. The semi-structured Nepali interview guide was pre-tested among two participants, and these interviews were not included in the final analysis.

3) Data collection: Authors mentioned that the data collected via telephone calls. It is recommended to describe how actually the interviews took place. The way of taking consent, time of the interview (approximate), what happened in the interview, was it recorded...? Additionally, did all the chosen participants have access to mobile phones?

If so, did all the selected participants respond? Were there any payments to the participants for participation in this interview.

Response: Thank you for your feedback this has been explained in the methodology section line 104-121

Considering the strict lockdown during the second wave of COVID-19 in Nepal, and to ensure the safety and convenience of both participants and RAs, all interviews were conducted over the phone. We did not use video platforms such as Zoom, as many participants did not have access to the internet, computers or the necessary skills to use such platforms. A total of 15 in-depth interviews were conducted with participants who reported experiencing some form of stigma. To assure the quality of the data collected, research Assistants (RAs) with prior qualitative research experience and familiarity with the local context conducted the interviews. This also helped to ensure neutrality thus limiting the chance of researcher's bias. Before the data collection process, the RAs were thoroughly trained on the study objectives, interview tools, and protocols to ensure quality in data collection. The RAs first contacted the participants who were purposively selected. All chosen participants were accessible via phone, either through their own device or that of a family member. During the initial contact, the study objectives, methods, and expectations were explained. As the interviews were conducted virtually, no compensation was provided to participants, and this was clearly communicated during the first contact. If participants consented to take part, they were given two options: to participate in the interview on the same day or to choose an alternative date and time based on their convenience. All interviews were conducted in Nepali. After consent, the interviews were recorded, and each lasted an average of 35 to 45 minutes.

5. Ethical considerations- Other than the informed consent, what other ethical aspects were concerned with?

Response: We have added more details in the revised manuscript as follows in line 138-149

The study was approved by the Institutional Ethics Committee of the Nepal Health Research Council (Reg. No. 2897). As the interviews were conducted remotely, informed verbal consent was obtained from all participants, an approach which was approved by the ethics committee. Before each interview, the RAs re-read the full consent script to participants and allowed time for any questions or clarifications. Once participants confirmed their understanding, verbal consent was audio-recorded. To maintain confidentiality, the consent recordings were stored separately from the interview recordings. RAs also checked if participants were in a comfortable space to share their perspectives and experiences, particularly given that many were confined at home with family members during the lockdown. All interview recordings and tran

Attachment

Submitted filename: Response to the reviewers .pdf

pone.0344123.s004.pdf (103.8KB, pdf)

Decision Letter 1

Surangi Jayakody

10 Nov 2025

Dear Dr. Bhandari,

==============================

Please submit your revised manuscript by Dec 25 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Surangi Jayakody, MBBS, MSc, MD

Academic Editor

PLOS ONE

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: (No Response)

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #1: No

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: N/A

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: In one place, you say ‘All participants in this study reported experiencing stigma from their families and community members, manifesting in various forms and intensities during their infection’ and then “No participants reported

direct discrimination from immediate family members”. This is confusing and contradictory. If people have not faced stigma from family, then do not mention it as such in the first sentence.

The code you have ‘discrimination by family and friends, ’ also problematic, as you move on to say there was no discrimination. If this is the case, then term in as a ‘Lack of discrimination by family and friends’. Please go through the codes and reword as appropriate.

I do not think the authors have understood my previous comment about the need to discuss the findings of this study in relation to the current COVID-19-free context? Authors should address the context-specific nature of COVID-19 stigma, as it may now be almost non-existent. unlike the stigma surrounding, for example, HIV/AIDS or NTDs. This is because COVID-19-related stigma is likely to be temporary and does not exist now? Another angle could be how or whether these stigma experiences of these patients will affect help-seeking behaviours for other diseases as well? Will they have long-term socio-cultural effects? These need to be critiqued.

The conclusion of this study needs to be thoroughly revised.

In the Conclusion, the authors say “these findings emphasize the urgent need for comprehensive interventions to combat stigma and discrimination” but now that COVID is over, is the stigma still there? Is it still relevant to suggest something like that? What you need to suggest is how these findings can be used for future preparedness of such outbreaks.

Again, I question the relevance of this sentence to the current context. The key recommendations include implementing mass education and awareness campaigns to improve knowledge about disease transmission, prevention, and control, establishing platforms for accessing accurate

information, strengthening reporting systems, enhancing the capacity of health institutions, and developing robust social protection mechanisms to support individuals facing stigma.’ Are people still not aware of COVID? Is this suggestion relevant to the current context?

Reviewer #2: All the comments of the previous review have been addressed adequately by the authors in this submission.

The manuscript of the qualitative study on "COVID-19 stigmatisation and its impact on survivors in Nepal" is written in scientifically and addressed the multifaceted stigma in a coherent way.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Mar 6;21(3):e0344123. doi: 10.1371/journal.pone.0344123.r004

Author response to Decision Letter 2


17 Dec 2025

Response to Reviewer’s comments – PONE-D-24-58430R1

We thank the editor and reviewers for their time, careful assessment, and constructive feedback which have significantly improve the quality of our manuscript. All comments have been addressed thoroughly, and point-by-point responses to all the comments are provided below

1. Reviewer #1: In one place, you say ‘All participants in this study reported experiencing stigma from their families and community members, manifesting in various forms and intensities during their infection’ and then “No participants reported

direct discrimination from immediate family members”. This is confusing and contradictory. If people have not faced stigma from family, then do not mention it as such in the first sentence.

Response: Thank you for highlighting this inconsistency. We agree that the original wording was unclear and potentially misleading. We have revised the manuscript to clearly distinguish between stigma experienced from community members and experiences within the family context.

In the Results section, we now state that all participants reported experiencing stigma directed at themselves and, in some cases, their families from community members and neighbours following disclosure of their COVID-19 status. We further clarify that direct discrimination from immediate family members was largely absent, except one participant who described internalized stigma within the family context, where self-directed fear of infection shaped his behaviour rather than overt discriminatory actions. These clarifications are reflected consistently in both the Results and Discussion sections of the revised manuscript. (Line 216-223,429-435)

2. The code you have, ‘discrimination by family and friends, ’ is also problematic, as you move on to say there was no discrimination. If this is the case, then term in as a ‘Lack of discrimination by family and friends’. Please go through the codes and reword as appropriate.

Response: Following this review, we refined the wording of several codes to better reflect the underlying data. Importantly, we removed any code that implied direct discrimination by immediate family members, as the data indicated that family-level stigma was limited to internalized stigma in one participant rather than overt discriminatory behaviour. As such, a separate code for family discrimination was not retained.

Under Theme 1, the revised codes now include: internalized stigma due self-directed fear of infection, perceived stigma, strained social relationships, reduced social support, intersecting stigma, discrimination in community and workplace settings, and stigma directed towards family members of COVID-19 survivors. These refinements are presented in Table 2. The revisions reflect improved clarity and precision in coding and do not alter the study results or their interpretation.

We appreciate the reviewer’s thoughtful guidance, which has strengthened the conceptual clarity of the analysis.

3. I do not think the authors have understood my previous comment about the need to discuss the findings of this study in relation to the current COVID-19-free context? Authors should address the context-specific nature of COVID-19 stigma, as it may now be almost non-existent. unlike the stigma surrounding, for example, HIV/AIDS or NTDs. This is because COVID-19-related stigma is likely to be temporary and does not exist now? Another angle could be how or whether these stigma experiences of these patients will affect help-seeking behaviors for other diseases as well? Will they have long-term socio-cultural effects? These need to be critiqued.

Response: Thank you for this clarification. We agree that COVID-19-related stigma is context-specific and likely to be time-limited, and this is now explicitly addressed in the revised discussion section.

The discussion situates the findings within the early and acute phases of the COVID-19 pandemic, shaped by uncertainty, self-directed fear of infection, and restrictive public health measures. It acknowledges that such stigma may no longer be prominent in the current context. We also distinguish COVID-19-related stigma from more enduring forms of stigma, such as those associated with HIV/AIDS or neglected tropical diseases. Rather than implying persistence of COVID-19 stigma, the revised discussion frames the relevance of the findings in terms of lessons for future public health emergencies, including implications for risk communication, continuity of essential health services, and potential effects on help-seeking behaviours during future outbreaks. [Line 451-456, 401-409,479-483-511]

4. The conclusion of this study needs to be thoroughly revised.

In the Conclusion, the authors say “these findings emphasize the urgent need for comprehensive interventions to combat stigma and discrimination” but now that COVID is over, is the stigma still there? Is it still relevant to suggest something like that? What you need to suggest is how these findings can be used for future preparedness of such outbreaks. Again, I question the relevance of this sentence to the current context. The key recommendations include implementing mass education and awareness campaigns to improve knowledge about disease transmission, prevention, and control, establishing platforms for accessing accurate

information, strengthening reporting systems, enhancing the capacity of health institutions, and developing robust social protection mechanisms to support individuals facing stigma.’ Are people still not aware of COVID? Is this suggestion relevant to the current context?

Response: Thank you for highlighting this important issue. We agree that framing COVID-19-related stigma as ongoing would not be appropriate in the current context. In response, we have substantially revised the conclusion to remove language implying an urgent need to address ongoing COVID-19-related stigma.

The revised conclusion now explicitly acknowledges that COVID-19-related stigma has likely diminished in the post-pandemic period. Recommendations are no longer framed as current COVID-19 interventions but instead emphasize how the findings can inform future outbreak preparedness and response, including transferable lessons related to communication, health system capacity, and social protection during public health emergencies. (Line 476-489)

In response to the reviewer’s emphasis on the post-pandemic context, we also reviewed the manuscript more broadly. We revised the abstract and introduction sections to ensure that the study is clearly framed as examining stigma during the acute phase of COVID-19, with relevance for future public health emergencies rather than the current COVID-19 context.

Reviewer #2: All the comments of the previous review have been addressed adequately by the authors in this submission.

Response: We thank the reviewer for their constructive comments, which have helped us substantially improve the quality and clarity of the manuscript.

Attachment

Submitted filename: Rebuttal letter.pdf

pone.0344123.s005.pdf (171KB, pdf)

Decision Letter 2

Habil Otanga

16 Feb 2026

“It becomes more difficult when people don’t empathize with us": COVID-19-related stigmatization experienced by survivors in Nepal.

PONE-D-24-58430R2

Dear Dr. Buna Bhandari,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support .

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Habil Otanga, Ph.D

Academic Editor

PLOS One

Additional Editor Comments (optional):

Reviewer comments and suggestions at Round 1 and 2 of revisions are noted as conclusively attempted.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #2: Yes

**********

Reviewer #2: The comments made by me in the previous version was addressed by the authors and in this version, further valid comments raised by other reviewer has been addressed.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #2: No

**********

Acceptance letter

Habil Otanga

PONE-D-24-58430R2

PLOS One

Dear Dr. Bhandari,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Habil Otanga

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Additional information.

    (DOC)

    pone.0344123.s001.doc (55.5KB, doc)
    Attachment

    Submitted filename: PONE-D-24-58430_ED.docx

    pone.0344123.s002.docx (185.4KB, docx)
    Attachment

    Submitted filename: Response to the reviewers .pdf

    pone.0344123.s004.pdf (103.8KB, pdf)
    Attachment

    Submitted filename: Rebuttal letter.pdf

    pone.0344123.s005.pdf (171KB, pdf)

    Data Availability Statement

    All relevant data are within the paper and its Supporting information files.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES